218 related articles for article (PubMed ID: 22407250)
1. Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells.
Garg M; Madan J; Pandey RS; Sardana S; Katyal A; Chandra R
Anticancer Drugs; 2012 Sep; 23(8):836-45. PubMed ID: 22407250
[TBL] [Abstract][Full Text] [Related]
2. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
[TBL] [Abstract][Full Text] [Related]
3. Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells.
Villa R; Cerroni B; Viganò L; Margheritelli S; Abolafio G; Oddo L; Paradossi G; Zaffaroni N
Colloids Surf B Biointerfaces; 2013 Oct; 110():434-42. PubMed ID: 23759384
[TBL] [Abstract][Full Text] [Related]
4. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
[TBL] [Abstract][Full Text] [Related]
5. Galactosylated chitosan-grafted multiwall carbon nanotubes for pH-dependent sustained release and hepatic tumor-targeted delivery of doxorubicin in vivo.
Qi X; Rui Y; Fan Y; Chen H; Ma N; Wu Z
Colloids Surf B Biointerfaces; 2015 Sep; 133():314-22. PubMed ID: 26123852
[TBL] [Abstract][Full Text] [Related]
6. Efficacious hepatoma-targeted nanomedicine self-assembled from galactopeptide and doxorubicin driven by two-stage physical interactions.
Ding J; Xiao C; Li Y; Cheng Y; Wang N; He C; Zhuang X; Zhu X; Chen X
J Control Release; 2013 Aug; 169(3):193-203. PubMed ID: 23247039
[TBL] [Abstract][Full Text] [Related]
7. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
8. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D
AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957
[TBL] [Abstract][Full Text] [Related]
9. Galactosylated poly(ethylene glycol)-b-poly (l-lactide-co-β-malic acid) block copolymer micelles for targeted drug delivery: preparation and in vitro characterization.
Suo A; Qian J; Yao Y; Zhang W
Int J Nanomedicine; 2010 Nov; 5():1029-38. PubMed ID: 21170351
[TBL] [Abstract][Full Text] [Related]
10. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
[TBL] [Abstract][Full Text] [Related]
12. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
[TBL] [Abstract][Full Text] [Related]
13. [Preparation of doxorubicin encapsulated in amphiphilic polysaccharide nanoparticles and anti-hepatocarcinoma effect thereof].
Huang YF; Gu WL; Li ZH; Chen RF; Zhou JJ; Zhou QB; Guo N
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):810-2. PubMed ID: 19595118
[TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacokinetics, biodistribution and the anti-tumor effect of cyclic RGD-modified doxorubicin-loaded polymers in tumor-bearing mice.
Wang C; Li Y; Chen B; Zou M
Colloids Surf B Biointerfaces; 2016 Oct; 146():31-8. PubMed ID: 27244048
[TBL] [Abstract][Full Text] [Related]
15. Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo.
Hossain MA; Kim DH; Jang JY; Kang YJ; Yoon JH; Moon JO; Chung HY; Kim GY; Choi YH; Copple BL; Kim ND
Int J Oncol; 2012 May; 40(5):1636-42. PubMed ID: 22322725
[TBL] [Abstract][Full Text] [Related]
16. Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma.
Wang B; Yuan Y; Han L; Ye L; Shi X; Feng M
J Drug Target; 2014 Jan; 22(1):76-85. PubMed ID: 24093636
[TBL] [Abstract][Full Text] [Related]
17. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
18. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
20. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
